Clinical trial
EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate…
NCT00230568 · Eisai Inc., Industry · Completed
Key facts
| NCT number | NCT00230568 |
|---|---|
| Title | EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD) |
| Official title | A 12-Week, Multicenter, Open-Label Study to Evaluate the Effectiveness and Safety of Donepezil Hydrochloride (Aricept) in Hispanic Patients With Mild to Moderate Alzheimer's Disease |
| Lead sponsor | Eisai Inc., Industry |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | Aricept |
| Enrollment | 100 |
| Start date | Dec 1, 2005 |
| Primary completion | Apr 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Oct 3, 2005 |
| Last update posted | Apr 1, 2011 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: